Physician profile
Katie Lowry
NPI 1700888518
$1,792.35
in general payments reported to CMS, 2019-2025
15 companies · $138 in 2025
The $138 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.82 · 2020: $102 · 2021: $814 · 2022: $469 · 2023: $94.55 · 2024: $103 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $781.10 | 2021 | |
| Baxter Healthcare | $468.66 | 2022 | |
| Ironshore Pharmaceuticals INC. | $116.15 | 2019-2020 | |
| Sanofi Pasteur INC. | $89.12 | 2024-2025 | |
| Pfizer INC. | $83.75 | 2019-2024 | |
| Glaxosmithkline, LLC. | $66.79 | 2019-2024 | Bexsero, Rotarix, Pediarix |
| Merck Sharp & Dohme LLC | $34.21 | 2023-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Aytu Biopharma, INC. | $27.53 | 2023-2024 | Karbinal |
| Seqirus USA INC | $25.30 | 2025 | Flucelvax |
| Abbott Laboratories | $22.16 | 2025 | Id Now Instrument |
| Azurity Pharmaceuticals, INC. | $21.48 | 2025 | Alvesco |
| Supernus Pharmaceuticals, INC. | $19.16 | 2024 | Qelbree |
| Neos Therapeutics, Lp | $13.81 | 2023 | Cotempla Xr-Odt |
| Corium, LLC | $12.35 | 2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $10.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.